All In Biotech

Drug Trial Radar · NCT07746544

Study of Secutrelvir in Participants With COVID-19

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Aug 5, 2026

Primary completion

Jul 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.

Conditions

  • COVID-19

Interventions

  • SecutrelvirDrug

    Secutrelvir will be administered orally as a tablet.

  • PlaceboDrug

    Placebo will be administered orally as a tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 21Time frame: Baseline through Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Japanese Site 1

    Multiple Locations, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.